Invesco
TARS icon

Invesco’s Tarsus Pharmaceuticals TARS Stock Holding History

Invesco’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.5M Buy
785,808
+43,311
+6% +$2.77M ﹤0.01% 1115
2026
Q1 		$52.1M Sell
742,497
-269,860
-27% -$18.9M 0.01% 1065
2025
Q4 		$82.9M Buy
1,012,357
+75,351
+8% +$5.63M 0.01% 904
2025
Q3 		$55.7M Buy
937,006
+8,505
+0.9% +$419K 0.01% 1044
2025
Q2 		$37.6M Buy
928,501
+101,978
+12% +$4.59M 0.01% 1174
2025
Q1 		$42.5M Sell
826,523
-105,592
-11% -$5.22M 0.01% 1104
2024
Q4 		$51.6M Buy
932,115
+250,018
+37% +$11.4M 0.01% 1026
2024
Q3 		$22.4M Buy
682,097
+290,534
+74% +$8.17M ﹤0.01% 1417
2024
Q2 		$10.6M Buy
391,563
+167,994
+75% +$5.65M ﹤0.01% 1759
2024
Q1 		$8.13M Buy
223,569
+125,696
+128% +$3.7M ﹤0.01% 1937
2023
Q4 		$1.98M Buy
+97,873
New +$1.63M ﹤0.01% 2615
2023
Q3 		– Sell
-41,769
Closed -$755K – 3909
2023
Q2 		$755K Sell
41,769
-19,409
-32% -$309K ﹤0.01% 3022
2023
Q1 		$769K Buy
61,178
+4,444
+8% +$65K ﹤0.01% 3033
2022
Q4 		$832K Buy
56,734
+16,071
+40% +$266K ﹤0.01% 3018
2022
Q3 		$696K Sell
40,663
-1,954
-5% -$31K ﹤0.01% 3072
2022
Q2 		$622K Buy
42,617
+14,635
+52% +$220K ﹤0.01% 3230
2022
Q1 		$471K Buy
27,982
+4,078
+17% +$75.7K ﹤0.01% 3421
2021
Q4 		$538K Sell
23,904
-4,710
-16% -$122K ﹤0.01% 3359
2021
Q3 		$616K Sell
28,614
-1,814
-6% -$44.9K ﹤0.01% 3333
2021
Q2 		$882K Buy
30,428
+1,169
+4% +$36.5K ﹤0.01% 3180
2021
Q1 		$943K Buy
29,259
+9,892
+51% +$366K ﹤0.01% 3068
2020
Q4 		$801K Buy
+19,367
New +$552K ﹤0.01% 3033

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Invesco's TARS Position: Q2 2026 in Review

Invesco increased its Tarsus Pharmaceuticals (TARS) stake by 5.8% in Q2 2026, buying an estimated $2.77M and bringing the position to 785,808 shares worth $49.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1115.

Invesco first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $82.9M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Invesco held 785,808 shares of Tarsus Pharmaceuticals worth $49.5M as of Q2 2026.
  • Invesco bought 43,311 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.77M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1115 holding.
  • Invesco first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Invesco's Tarsus Pharmaceuticals position peaked at $82.9M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.